Cautious Restart To Venetoclax’s CANOVA Trial In Multiple Myeloma
The US FDA has lifted a partial clinical hold on one study of venetoclax in multiple myeloma, but other trials of the first-in-class agent in the potential additional indication remain on hold.
You may also be interested in...
AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.
Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.
Only two novel oncologics have cleared the FDA’s approval bar in 2019, but the Pink Sheet’s user fee tracker shows at least eight candidates under review, along with seven significant new indications and formulations.